Cancer vaccines: Targeting KRAS-driven cancers

Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations

(2019) Susumu Iiizumi et al.   Cancers

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

(2019) J Mazières et al.   ANNALS OF ONCOLOGY

Cancer Vaccines

(2019) Peter J. DeMaria et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

(2018) Matthew R. Janes et al.   CELL

Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations

(2018) Allen Cohn et al.   JOURNAL OF IMMUNOTHERAPY

A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors

(2018) Tingting Wang et al.   Nature Communications

Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses

(2018) Jasmin Quandt et al.   OncoImmunology

KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer

(2018) Diana Casique-Aguirre et al.   BMC CANCER

Targeting metabolic reprogramming in KRAS-driven cancers

(2017) Kenji Kawada et al.   International Journal of Clinical Oncology

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer

(2017) Pasi A. Jänne et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer

(2017) Sushrut Kamerkar et al.   NATURE

T-Cell Transfer Therapy Targeting Mutant KRAS

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Personalized cancer vaccines: Targeting the cancer mutanome

(2017) Xiuli Zhang et al.   VACCINE

Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers

(2017) Laetitia Seguin et al.   Cancer Discovery

Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine

(2017) Jing Pan et al.   Oncotarget

Electroporation as a vaccine delivery system and a natural adjuvant to intradermal administration of plasmid DNA in macaques

(2017) Biliana Todorova et al.   Scientific Reports

Kras and Tumor Immunity: Friend or Foe?

(2017) Jane Cullis et al.   Cold Spring Harbor Perspectives in Medicine

A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling

(2016) Sai Krishna Athuluri-Divakar et al.   CELL

Dendritic Cell-Based Immunotherapy: State of the Art and Beyond

(2016) K. F. Bol et al.   CLINICAL CANCER RESEARCH

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

(2016) Zhong-Yi Dong et al.   CLINICAL CANCER RESEARCH

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

(2016) Johan F Vansteenkiste et al.   LANCET ONCOLOGY

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

(2016) Brian I Rini et al.   LANCET ONCOLOGY

KRAS-related proteins in pancreatic cancer

(2016) Karen M. Mann et al.   PHARMACOLOGY & THERAPEUTICS

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

(2016) P. Lito et al.   SCIENCE

Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines

(2016) S.H.T. Jorritsma et al.   VACCINE

Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer

(2016) Vincenzo Sforza et al.   WORLD JOURNAL OF GASTROENTEROLOGY

BGB-283 Deemed Effective in Phase I Study

(2016)   Cancer Discovery

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma

(2016) Barbara Bournet et al.   Clinical and Translational Gastroenterology

Chemo-immunotherapy mediates durable cure of orthotopic KrasG12D/p53−/− pancreatic ductal adenocarcinoma

(2016) Vanaja Konduri et al.   OncoImmunology

Improving Prospects for Targeting RAS

(2015) Harshabad Singh et al.   JOURNAL OF CLINICAL ONCOLOGY

RNA-Based Vaccines in Cancer Immunotherapy

(2015) Megan A. McNamara et al.   Journal of Immunology Research

Live bacterial vaccine vectors: An overview

(2015) Adilson José da Silva et al.   BRAZILIAN JOURNAL OF MICROBIOLOGY

Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation

(2014) Jamie E. Chaft et al.   Clinical Lung Cancer

A Listeria Vaccine and Depletion of T-Regulatory Cells Activate Immunity Against Early Stage Pancreatic Intraepithelial Neoplasms and Prolong Survival of Mice

(2014) Bridget P. Keenan et al.   GASTROENTEROLOGY

DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model

(2014) T-Y Weng et al.   GENE THERAPY

The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors

(2014) Osama E Rahma et al.   Journal of Translational Medicine

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3

(2014) Chong Sun et al.   Cell Reports

Clinical evaluation of therapeutic cancer vaccines

(2013) Chizuru Ogi et al.   Human Vaccines & Immunotherapeutics

An Updated View of the Intracellular Mechanisms Regulating Cross-Presentation

(2013) Priyanka Nair-Gupta et al.   Frontiers in Immunology

Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy

(2012) L. van de Laar et al.   BLOOD

Mutated Ras-Transfected, EBV-Transformed Lymphoblastoid Cell Lines as a Model Tumor Vaccine for Boosting T-Cell Responses Against Pancreatic Cancer: A Pilot Trial

(2012) Boris Kubuschok et al.   HUMAN GENE THERAPY

A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations

(2011) Gregory J. Riely et al.   Journal of Thoracic Oncology

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

(2011) Douglas J. Schwartzentruber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine

(2010) Ghassan K. Abou-Alfa et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras

(2010) Synne Wedén et al.   INTERNATIONAL JOURNAL OF CANCER

Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity

(2010) Mariola Fotin-Mleczek et al.   JOURNAL OF IMMUNOTHERAPY

Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers

(2008) Antoun Toubaji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

DNA vaccines: ready for prime time?

(2008) Michele A. Kutzler et al.   NATURE REVIEWS GENETICS